Pacira Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: (858) 625 2424
Website: http://www.pacira.com/
About Pacira Biosciences
At Pacira BioSciences, we have a capable and passionate team of people dedicated to serving our customers in a work environment that encourages collaboration. Our culture inspires and challenges individuals to be effective and efficient in all that they do, and our workforce has a passion for excellence.
OWNERSHIP: Public
Stock Exchange: NASDAQ
STOCK SYMBOL: PCRX
194 articles about Pacira Biosciences
-
4 Biotech Stocks That Could Triple In Value This Year
8/4/2016
-
Pacira to Pay Termination Fee of About $7.3 Million to CrossLink
7/1/2016
-
Insulet and Pacira, Two Companies with Massive Upside Potential
6/24/2016
-
Pacira Reports First Quarter 2016 Financial Results
5/2/2016
-
Pacira Received Favourable Resolution With U.S. FDA Relating To EXPAREL
12/15/2015
-
Pacira Release: New Study Finds Decreased Opioid Use, Hospital Stay, And Readmission Rates With EXPAREL Following Knee Replacement Surgery
11/6/2015
-
Pacira Seeks Court Injunction To Defend Its Rights To Share Information About EXPAREL Consistent With Its FDA-Approved Indication
9/9/2015
-
Pacira Appoints James B. Jones, MD, PharmD, As Senior Vice President And Chief Medical Officer
8/19/2015
-
Pacira To Present At Investor Conferences In August
8/3/2015
-
Pacira Reports Second Quarter 2015 Financial Results
7/30/2015
-
Pacira Announces Timing For Second Quarter 2015 Financial Results Webcast And Conference Call
7/15/2015
-
Pacira Appoints Scott Braunstein, MD, To Oversee Strategy And Corporate Development
7/14/2015
-
Pacira Announces Completion Of End-of-Review Process With FDA Regarding EXPAREL sNDA For Nerve Block
5/28/2015
-
Pacira To Present At Investor Conferences In June
5/21/2015
-
Pacira Announces New Data Supporting Clinical And Pharmacoeconomic Utility Of EXPAREL In Patients Undergoing Various Surgical Procedures
5/20/2015
-
Pacira Reports First Quarter EXPAREL Revenues Of $56.0 Million And First Quarter 2015 Financial Results
4/30/2015
-
Pacira Receives Subpoena From The U.S. Department Of Justice
4/16/2015
-
Pacira Announces Timing For First Quarter 2015 Financial Results Webcast And Conference Call
4/13/2015
-
Pacira Announces New Data On Health Economic Benefits Of EXPAREL For Postsurgical Pain Control Following Total Knee Replacement Surgery
4/10/2015
-
Pacira Announces Data Reinforcing Benefits Of EXPAREL For Postsurgical Pain Control Following Total Hip And Knee Replacement Surgery
3/26/2015